ISPOR Europe 2024

  • Nov 17 - Nov 20, 2024
  • Barcelona, Spain
  • Booth #901

  • 17 - 20 November, 2024
  • Barcelona, Spain
  • Booth #901

Request a meeting

Join Us at ISPOR Europe

Connect with Evidera and CorEvitas experts specializing in health economics and outcomes research (HEOR), health economics and market access (HEMA), patient-centered research (PCR), and real-world data (RWD) and evidence (RWE). Our multi-disciplinary team was purpose-built to provide integrated solutions across the product development and commercialization lifecycle. Our deep expertise and proprietary real-world data offerings are designed to simplify your complex research needs, providing seamless support from initial development to market access.

Visit us at Booth # 901 or schedule a meeting on-site to discuss our customized offerings.

Digital Handouts

EU HTA Overview
Partnership with ConcertAI
Real-world Evidence for Real-life Insights
Real-world Evidence Studies – Diverse Data Designs
Registries and Real-World Evidence

Are you ready for the EU HTA Regulation changes?

Book a free consultation at ISPOR EU with our health economic and value access experts to discuss the complex nuances of the evolving EU market access landscape. Let our experts help you navigate the implications of the new regulation to uncover potential hurdles in your HTA strategy.

Request a meeting

Private Workshops at ISPOR EU – RSVP to attend

Patient Preferences Meetup

Sunday, 17 November • 6:00pm – 8:00pm

Register to save your spot

EU HTA Regulation Session

Monday, 18 November • 7:00pm – 9:30pm

Register to save your spot

Our Solutions

insert image
Which patient engagement strategies will optimize your clinical study?

Learn more

insert image
Can our real-world data and evidence solutions fast-track approval and secure market access for your asset?

Learn more

insert image
Are you ready for the new EU HTA Regulation changes?

Learn more

HEOR Theatre Presentation

Tuesday, 19 November • 3:45pm – 4:15pm

Poster and Exhibit Hall, 021, Level P0, Theater 2

Better and Faster: Automating Model Building and Statistical Analyses

Presenters: Jack Ishak, Apoorva Ambavana

Moderator: Agnes Benedict

ISPOR Forum

Tuesday, 19 November • 11:45am – 12:45pm

Using Health Preference Methods for Value Clarification in Patient Decision Support: Current Use and Future Developments

Speaker: Caitlin Thomas

Symposia & Workshop Sessions

Session 2

Monday, 18 November • 5:00pm – 6:00pm

How Do We Unleash the Ambition of the EU HTA Regulation through Practical Methodological Solutions?

Moderator: Martin Parkinson

Panelists: Anna Chaimani, Niklas Hedberg, James Ryan

Session 3

Tuesday, 19 November • 1:45pm – 2:45pm

How Can We Move from Generating Robust Patient Preference Information to Producing Decision-Ready Outputs?

Discussion Leader: Sebastian Heidenreich

Discussants: Paul Schneider, Divya Mohan

Session 4

Tuesday, 19 November • 5:00pm – 6:00pm

Interplay Between Budget Impact Analysis (BIA) and Cost-Effectiveness Analysis (CEA); Theory vs Practice

Moderator: Cornelis Boersma

Panelists: Jaime Caro, Josephine Mauskopf, Thea van Asselt

Session 5

Wednesday, 20 November • 10:00am – 11:00am

Taking the “Greener” Pill – a Case Study for Incorporating Carbon Footprint in Health Technology Assessment

Discussion Leader: Ruth Chapman

Discussants: Michael Cohen, Grace Hampson, Kinga Marczell

Poster Presentations





Session 1

Monday, 18 November

Authoring of Peer-Reviewed Articles on the Experiences of Patients With Rare Diseases by Patients and Their Caregivers: A Rapid Review

Phil Leventhal, Danielle Drachmann, Rienne Schinner, Soren Skovlund

Validation of a Questionnaire to Assess Emotional Impact of Treatment for Type 2 Diabetes (EIDTQ)

Louis Matza, Katelyn Cutts, Karen Malley, Karin Coyne

Patient Preferences of Health State Utilities Associated With Glycemic Variability in People Living With Type 1 and Type 2 Diabetes

Louis Matza, Katie Stewart

A Systematic Literature Review of Economic Burden and Medication Adherence With Subcutaneous Versus Intravenous Oncology Therapies

Carolina Casañas Comabella, Phil Sarocco

Understanding physicians decision making processes when treating mild-to-moderate chronic kidney disease: A qualitative study

Keila Meginnis

Does Baseline Disease Severity Impact the Meaningful Score Difference of Clinical Outcome Assessments? Results From Studies in Two Itching-Related Skin Conditions

Danielle Rodriguez, Carla Dias-Barbosa, Karen Bailey, Dina Filipenko

The Burden of Long COVID on Quality of Life and Daily Functioning

Naomi Stapleton, Heather Burnett, Jennifer Knight

Estimated Cost of Automated Red Cell Exchange Transfusion (ARCET) for Treatment of Sickle Cell Disease (SCD) in the English NHS: Data from a Longitudinal Real-World Cohort

Caoimhe Rice, Sara Carvalho, Jennifer Davidson

Polihexanide and betaine (PSGX) containing solution versus saline for the treatment of leg uclers: A comparative cost analysis study using real-world data from England

Caoimhe Rice, Jennifer Davidson

Session 2

Monday, 18 November

Artificial Intelligence Tools for PICO Prediction: A New Reality or a Future Dream?

Himani Jaiswal, Paulina Rolska-Wójcik, Caroline Delaitre-Bonnin

Patient Preferences and Health State Utilities Associated With Frequency of Basal Insulin Administration for Type 1 and Type 2 Diabetes

Katie Stewart, Louis Matza

Incidence of Solar Retinopathy and Photokeratitis in Private Clinic Post 2017 and 2024 Solar Eclipses Across the USA

Nick Boucher

Comparison of Methods for Extrapolation of Drug Survival of Biologics in Psoriasis NICE Submission Cost-Effectiveness Analyses

Paulina Kazmierska, George Bungey

Real-world Healthcare Resource Utilization and Costs in Patients with Locally Advanced or Metastatic Urothelial Carcinoma in China

Lu Ban

Use of a Fine-Tuned, Clinical, Bidirectional Transformer (BERT) Large Language Model (LLM) to Classify the Patient and Caregiver Voice Through Their Social Media Health Posts: An Example in Non-Small Cell Lung Cancer (NSCLC)

Ashwin Rai, Victoria Ikoro, Ariel Berger

How Real Is Your Real-World Evidence (RWE)? Demonstration of the Need for Comprehensive Real-World Data (RWD) to Examine Patient Burden and Disease Journey in Patients With Sickle Cell Disease (SCD) in the United States (US)

Ariel Berger

Session 3

Tuesday, 19 November

A Framework for Re-Thinking Evidence Generation Requirements in the United States: It’s Time to Meet Expectations of the Inflation Reduction Act

Anna D’Ausilio, Rhythm Arora, Brian Connelly, Ariel Berger, Haripriya Jain

Representativeness and Coverage of Death Data in the DeSC Healthcare Database in Japan

Ayumi Hamaguchi, Amanda Pulfer, Dimitra Lambrelli

Understanding the Patient Experience in Early Breast Cancer (eBC): A Review of Patient-Reported Outcomes Measures (PROMs) Used in Real-World Evidence (RWE)

Ashley Duenas, Claudine Clucas, Klaudia Kornalska, Paul Swinburn

Session 4

Tuesday, 19 November

Leveraging the DeSC Healthcare Database for Alzheimer’s Disease (AD) Research in an Aging Population in a Real-World Setting in Japan

Ayumi Hamaguchi, Amanda Pulfer, Dimitra Lambrelli

Development of a US-Based, Real-World, Ophthalmology Registry Based on Automated EHR Data Extraction to Support Opportunities for Clinical and Health Economics and Outcomes Research in Eyecare

Nick Boucher, Ariel Berger

Characteristics of Ovarian Cancer Patients: A Real-World Perspective for 1st Line Maintenance Treatment Choice After 1st Line Platinum Based Induction Therapy Across EU4 & UK

Karina Palhares

Deriving an Analytical Solution to Inversion of Royston/Parmar Restricted Cubic Spline Parametric Survival Models for Discrete Event Simulation

George Bungey, Jorgen Moller

How to Manage the Multiple PICOs and Challenging Timelines in Systematic Reviews for JCA Submissions

Sohan Deshpande

Feasibility of GPT-4-Based Content Extraction to Identify Eligible Titles and Abstracts in a Systematic Literature Review (SLR)

Lalith Mittal

Automated Extraction of Cost-Effectiveness Models Data from Health Technology Assessment Submissions Using Large-Language Models (LLMS): Does the Prompting Approach Matter?

Gabor Szabo, Amy Pinsent, Mahmoud Slim, Shannon Sullivan, Agnes Benedict, Simone Rivolo

Long COVID: A Costly Condition Imposing Substantial Burden on Society

Jennifer Knight, Heather Burnett, Naomi Stapleton

Gap Analysis of Patient-Reported Outcome Measures for Systemic Lupus Erythematosus

Milena Anatchkova, Tsion Fikre

Session 5

Wednesday, 20 November

Assessment of Health State Utilities Associated With Being a Caregiver for a Person With Alzheimer’s Disease With Mild Cognitive Impairment or Dementia

Louis Matza, Timothy Howell

Unlocking the Potential of Interoperable Linked Low-Latency National Health Data in England to Protect Vulnerable Patients While Safeguarding their Privacy: A Brave New World

Nahila Justo, Yi Lu, Kathryn Evans, Valerie Olson, David Turner

Automated Data Extraction in Systematic Literature Reviews (SLRs): Assessing the Accuracy and Reliability of a Large Language Model (LLM)

Carolina Casañas Comabella

Improper Age-Adjustment of Health State Utilities in Cost-Effectiveness Models: Assessing the Impact and Key Drivers

Walter Morris, George Bungey

Searching Clinical Trial Registries in Systematic Literature Reviews (SLR): Which and Why?

Lalith Mittal

Estimated Incremental Direct All-Cause Healthcare Costs Associated with Multimorbidity Amongst Patients with Sickle Cell Disease (SCD) in England

Caoimhe Rice, Sara Carvalho, Jennifer Davidson

Understanding the experiences of people living with chronic pruritus of unknown origin: Development of a disease conceptual model

Carla Dias Barbosa, Karen Bailey

Development of a Conceptual Disease Model of the Patient Experience of Systemic Lupus Erythematosus

Milena Anatchkova, Tsion Fikre

    Share this...